US FDA reviewer urges taking Avandia off the market

(Reuters) - Senior FDA officials say they do not know if Avandia
increases heart-attack risk and are asking the advisory panel
if the drug should come off the market or stay with stronger
warnings or limits. Panel recommendations are expected on
Monday afternoon.





Read more at Reuters.com Government Filings News